| pubmed-article:19814645 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19814645 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19814645 | lifeskim:mentions | umls-concept:C0010762 | lld:lifeskim |
| pubmed-article:19814645 | lifeskim:mentions | umls-concept:C2609414 | lld:lifeskim |
| pubmed-article:19814645 | lifeskim:mentions | umls-concept:C1882417 | lld:lifeskim |
| pubmed-article:19814645 | lifeskim:mentions | umls-concept:C0205254 | lld:lifeskim |
| pubmed-article:19814645 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19814645 | pubmed:dateCreated | 2009-10-9 | lld:pubmed |
| pubmed-article:19814645 | pubmed:abstractText | Medications are a major source of acute kidney injury, especially in critically ill patients. Medication-induced renal injury can occur through a number of mechanisms. We present two cases of acute kidney injury (AKI) where inactive cytochrome P450 (CYP) polymorphism may have played a role. The first patient developed a biopsy-proven allergic interstitial nephritis following urethrotomy. Genetic testing revealed the patient to be heterozygous for an inactivating polymorphism CYP2C9*3 and homozygous for an inactivating polymorphism CYP2D6*4. Patient had received several doses of promethazine, which is metabolized by CYP2D6*4. Another patient developed AKI on several occasions after exposure to lansoprazole and allopurinol. CYP testing revealed the patient to be homozygous for inactivating polymorphism CYP2C19*2, which is responsible for the metabolism of lansoprazole. These are the first two cases of AKI associated with non-functional polymorphisms of cytochrome P450 superfamily. While the exact mechanism has not been worked out, it introduced the possibility of a new source of kidney injury. | lld:pubmed |
| pubmed-article:19814645 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19814645 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19814645 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19814645 | pubmed:issn | 1525-6049 | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:MaddoxDaniel... | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:LeungNelsonN | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:FervenzaFerna... | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:GarovicVesna... | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:GundersonHeid... | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:EirinAlfonsoA | lld:pubmed |
| pubmed-article:19814645 | pubmed:author | pubmed-author:IrazabalMaria... | lld:pubmed |
| pubmed-article:19814645 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19814645 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:19814645 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19814645 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19814645 | pubmed:pagination | 749-52 | lld:pubmed |
| pubmed-article:19814645 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:meshHeading | pubmed-meshheading:19814645... | lld:pubmed |
| pubmed-article:19814645 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19814645 | pubmed:articleTitle | Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. | lld:pubmed |
| pubmed-article:19814645 | pubmed:affiliation | Mayo Clinic Rochester, Division of Nephrology and Hypertension, Rochester, Minnesota, USA. Leung.nelson@mayo.edu | lld:pubmed |
| pubmed-article:19814645 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19814645 | pubmed:publicationType | Case Reports | lld:pubmed |
